Trial Profile
Bioequivalence of mometasone [Watson Laboratories] with Nasonex [Schering] for seasonal allergic rhinitis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Aug 2020
Price :
$35
*
At a glance
- Drugs Mometasone (Primary)
- Indications Seasonal allergic rhinitis
- Focus Registrational; Therapeutic Use
- 18 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 May 2013 New trial record